Abiraterone is analogue that can effectively and irreversibly inhibit the CYP17 enzyme in the human body. Therefore, it can inhibit the synthesis of androgens from the source and inhibit the growth of androgen-dependent prostate cancer. Abiraterone was approved by the FDA in 2012 for the treatment of metastatic castration-resistant prostate cancer.
https://www.medixocentre.com/abiraterone-cost ↗